In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Quadra Mining Ltd.

Eisai And Eli Lilly Triumph At The 19th Annual Scrip Awards

Eisai and Lilly were the biggest winners at the 19th Annual Scrip Awards in a glittering ceremony at the Dorchester in London’s Mayfair, hosted by the actor and comedian Jon Culshaw.

Companies Commercial

Q32 Bio Resets As A Public Company With Two Mid-Stage Assets

The company announced a reverse merger with Homology Medicines that will take the company public while also regaining full rights from Amgen to bempikibart for atopic dermatitis and alopecia areata.

Financing StartUps and SMEs

Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies

Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.

Deal Watch Business Strategies

TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza

Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.

Clinical Trials Business Strategies
See All

Company Information

UsernamePublicRestriction

Register